Purple (NASDAQ:PRPL) Misses Q2 CY2026 Sales Expectations

Purple (NASDAQ:PRPL) reported Q2 CY2026 revenue of $98.27 million, down 6.5% year on year, missing market expectations. Non-GAAP adjusted EPS was -$1.52, better than analysts’ consensus. For next quarter, management guided revenue to $430 million at the midpoint. The article also notes negative operating margin and ongoing revenue decline.

Original reporting
Published Aug 10, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Purple (NASDAQ:PRPL) Misses Q2 CY2026 Sales Expectations — source image
Decision brief

The 30-second read

$PRPLNeutralMed
01

Why it matters

Q2 revenue missed and profitability remains weak, but the company’s next-quarter revenue guidance (midpoint $430M) is far above consensus estimates, which can materially shift near-term expectations and positioning.

02

Market read

This is a results-and-guidance update that can drive estimate revisions: EPS beat versus revenue miss, plus an unusually high next-quarter revenue outlook.

03

What to watch

The article highlights operating margin at -4.3% in Q2 and negative adjusted EPS, so traders may focus more on cash burn and cost structure than the revenue guide alone.

Relevance 8/10Novelty 6/10Timing: after-hours/overnight following Q2 CY2026 results

Background

Purple is a sleep and home comfort retailer; the article frames Q2 CY2026 as continued progress on controllables despite challenging industry conditions.

Company-level read

Ticker impact

$PRPLNeutralMedium confidence
Context

Purple reported Q2 CY2026 revenue of $98.27M, down 6.5% YoY, missing expectations, while guiding next-quarter revenue to $430M midpoint.

Expected impact

Near-term volatility likely, with traders weighing the revenue miss against the outsized next-quarter revenue outlook.

Evidence & confidence

The article provides concrete Q2 results (revenue, adjusted EPS) and a specific next-quarter revenue midpoint guide, which can drive revisions to near-term estimates despite weak profitability metrics.

Market effects

Consumer discretionary bedding demand signals remain soft, but a sharp guide could temporarily lift sentiment around select retailers with turnaround narratives.

No specific regional demand or macro linkage provided.

No direct global supply-chain or international demand details included.

Counterpoint

The next-quarter revenue guide may be difficult to underwrite given the company’s multi-year revenue decline and still-negative operating margins.

Key entities

  • Purple Innovation

    Reported Q2 CY2026 revenue of $98.27M (down 6.5% YoY) and guided next-quarter revenue to $430M midpoint.

  • Rob DeMartini

    CEO quoted on progress despite missing top-line expectations.

Related articles

$PRPLMed

Purple Innovation Reports Third Quarter 2026 Results

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT Purple Innovation Reports Third Quarter 2026 Results Positive Operating Cash Flow for the Third Consecutive Quarter Preparing for Major Mattress Portfolio Refresh to Strengthen Performance in 2027 Lehi, Utah, November 4, 2026 – Purple Innovation, I

$PRPLMedAI 8/10

Why Purple (PRPL) Stock Is Trading Lower Today

Purple (PRPL) shares fell 24.6% after the company reported Q2 revenue of $98.27 million, down 6.5% year over year and below Wall Street expectations. Adjusted EPS was a loss of $1.52, better than forecast. Purple kept full-year revenue guidance around $430 million, but investors focused on the quarterly sales miss.

$PRPLMed

Purple Innovation Reports Second Quarter 2026 Results

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Purple Innovation Reports Second Quarter 2026 Results Showroom Revenue Up 16.6% and Comparable Revenue Up 18% GAAP Net Loss of $3.2 Million in the Second Quarter Adjusted EBITDA Improves $4.4 Million to $2.1 Million Regains Compliance with Nasdaq Minimum Bid Price Re

Med

TELUS (TU) Q3 2026 Earnings Call Transcript

TELUS (TU) outlined three key priorities during its Q3 2026 earnings call: strengthening its financial foundation, honing operational discipline, and deploying resources for growth. The company aims to reduce debt, achieve a net debt to adjusted EBITDA leverage ratio of 3x or lower by 2028, and target $900 million in annualized cash savings by 2028. TELUS plans to monetize non-core assets, streamline operations, and invest in its PureFibre network for growth in AI infrastructure.

$PAHCMedAI 8/10

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.

$NOGMed

Northern Oil And Gas (NOG) Beat Expectations, But Is The Stock Still Cheap?

Northern Oil and Gas (NOG) reported record Q3 production and EBITDA, beating earnings expectations. The company raised its 2026 output guidance. Despite a 19.44% drop in the 7-day share price, the 1-year return is 14.36% and the 5-year return is 22.67%. The stock is trading at $22.84, with some analysts valuing it at $30.44, suggesting a 25% undervaluation. The company's focus on capital allocation and asset mix aims to support future earnings.